Roche chairman still expects diagnostics hit from US tariffs
Roche expects its agreement with the U.S. government will keep its medicines exempt from the current round of import tariffs, but its diagnostics division remains exposed and could face renewed duties after an initial 150-day period, Chairman Severin Schwan said on Saturday.
Roche Advances Obesity Pipeline as Petrelintide Meets Phase II Goal
RHHBY says the ZUPREME-1 study meets its goal as petrelintide delivers up to 10.7% weight loss with placebo-like tolerability, supporting further advancement.
Roche's BTK Drug Fenebrutinib Shines in Multiple Sclerosis Study
RHHBY's fenebrutinib slashes RMS relapses by 51% in phase III, advancing its bid for a first high-efficacy oral therapy in MS.
Roche targets double-digit market share in weight loss, aims to catch up with Novo Nordisk, Handelsblatt reports
Swiss pharmaceutical company Roche is aiming for a double-digit market share in the weight loss market and wants to close the gap on its Danish rival Novo Nordisk , its CEO told Germany's Handelsblatt business daily.
Roche Multiple Sclerosis Drug Meets Key Goal in Late-Stage Trial
The drugmaker said the results provide convincing evidence that fenebrutinib can become the first high-efficacy oral treatment for relapsing and primary progressive multiple sclerosis.
FDA Accepts Roche's NDA Seeking Approval for Breast Cancer Drug
FDA's acceptance of RHHBY's NDA for giredestrant plus everolimus in ER-positive breast cancer sets up a potential first oral SERD combo.
Roche Holding AG (RHHBY) Shareholder/Analyst Call Transcript
Roche Holding AG (RHHBY) Shareholder/Analyst Call Transcript
Roche's multiple sclerosis drug fenebrutinib meets goal in late-stage trial
Swiss pharmaceutical company Roche said on Saturday its experimental multiple sclerosis drug fenebrutinib met the main goal in a late-stage trial in patients with primary progressive multiple sclerosis, a rare form of the disease with few treatment options.
Roche Holding AG (RHHBY) Q4 2025 Earnings Call Transcript
Roche Holding AG (RHHBY) Q4 2025 Earnings Call Transcript
Roche's Full-Year Earnings: Solid, No Alarms - Obesity Promise Makes The Buy Case
Hoffman-La Roche aka Roche Holding AG delivered robust 2025 results, with core EPS up 11% CER and a resilient pharma division driving growth. RHHBY's pipeline, especially in obesity and cardiovascular, positions it as a potential third major player in the GLP-1 market. Management guides for mid-single digit sales and high-single digit core EPS growth in 2026, alongside a dividend increase.
RHHBY's 2025 Results Hit by Currency Headwinds, Sales Up 7% at CER
Roche's key drugs lift sales by 7% at CER despite FX headwinds. The company expects mid-single digit sales growth in 2026.
Roche Forecasts 2026 Growth, Helped by Strength of Drug Pipeline
The Swiss drugmaker said it expects sales to grow in the mid-single-digit range, with core EPS growth in the high-single-digit range at constant currencies.
